Pfizer Inc.'s cholesterol drug Lipitor’s patent ended in Canada and Spain and the medicine will lose protection in the U.S. in November. Photographer: JB Reed/Bloomberg
Pfizer Inc.'s cholesterol drug Lipitor’s patent ended in Canada and Spain and the medicine will lose protection in the U.S. in November. Photographer: JB Reed/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=295809861&utmp=%2Fphoto%2F2011-02-01%2Fpfizer-fourth-quarter-net-topss-analyst-estimates-shares-fall-on-outlook&utmhn=10.248.179.14&utmac=UA-11413116-12&utmhid=100604369)